COVID-19 Pandemic

Current status of authorisations for combating COVID-19

This table (“dashboard”) shows the applications received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.

All about the vaccines - briefly and concisely explained

Vaccines: Rapid solution for new diseases?

Swismedic - The way a vaccination works

How an mRNA vaccine works

How a vector vaccine works?

How a protein vaccine works

How is the safety of vaccines monitored?

Communication regarding COVID-19


Pfizer AG applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine

Application submitted for Comirnaty Original/Omicron BA.4-5


COVID-19 vaccine Nuvaxovid: temporary authorisation from 12 years of age and as booster

Swissmedic authorises indication extension and booster


Pfizer applies for indication extension of COVID-19 vaccine to include children aged 6 months to less than 5 years

Swissmedic reviews Pfizer Schweiz AG application for Comirnaty®


Out-of-Stock – COVID-19 – Authorisations for the temporary import and distribution of human medicines – Update

Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3


Swissmedic approves first bivalent COVID-19 booster vaccine in Switzerland

Moderna's Spikevax Bivalent Original/Omicron (mRNA-1273.214) authorised from age 18


Reports of suspected adverse reactions to COVID-19 vaccines

15,781 reports of suspected adverse vaccination reactions evaluated


Comirnaty® 30 micrograms/dose (PURPLE cap) – New shelf-life

Extended shelf live at ultra-low temperature


Empfehlung bezüglich COVID-19 für die autologe Blutstammzellspende

Beschluss Vorschriften SBSC – Blutstammzellspende


Pfizer applies for an authorisation extension for a coronavirus vaccine against Omicron

Comirnaty: Swissmedic starts rolling review of a bivalent COVID-19 vaccine


Changes to Guidance document Authorisation procedures for COVID-19 medicinal products during a pandemic HMV4

Filing of Submission Plans to evaluate the efficacy of existing COVID-19 medicinal products against new SARS-Cov-2 variants